Dr. Reshma Kewalramani serves as the Chief Executive Officer and President of Vertex Pharmaceuticals, where she leads the company’s efforts to develop transformative medicines that improve the lives of patients worldwide. A physician-scientist and accomplished industry leader, she has dedicated her career to advancing innovation in healthcare and accelerating the delivery of breakthrough therapies.
Since joining Vertex in 2017, Dr. Kewalramani has played a central role in expanding treatment options for people living with cystic fibrosis, helping drive the approvals of SYMDEKO/SYMKEVI and TRIKAFTA, therapies designed to benefit the majority of CF patients globally. Under her leadership, Vertex has also advanced promising programs in areas such as alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, sickle cell disease, and beta-thalassemia.
Prior to Vertex, she spent more than 12 years at Amgen in senior research and development leadership roles. Deeply committed to mentorship and community impact, Dr. Kewalramani actively supports initiatives that advance STEM education, scientific leadership, and public health.
